Inhaled Antibiotics for Pseudomonas in Bronchiectasis

"Inhaled Antibiotics for Pseudomonas in Bronchiectasis" takes up the decision points that guide inhaled antibiotic use in bronchiectasis patients with pseudomonas.

Dr. Basavaraj asks Dr. Khabbaza how he approaches inhaled antibiotics, particularly for patients whose sputum grows pseudomonas, an organism associated with worse bronchiectasis outcomes. Dr. Khabbaza explains that his starting point is always optimizing airway clearance regardless of pseudomonas status, followed by an oral antibiotic regimen if the organism is newly identified. Patients who respond well and remain stable on airway clearance alone typically stay at that level of care.

For patients who continue exacerbating, Dr. Khabbaza moves more quickly toward inhaled antibiotics. He describes a typical pattern: a patient treated with a fluoroquinolone who improves temporarily, then flares again a month or two later while still growing pseudomonas. Because pseudomonas colonization worsens long-term outcomes, he aims to suppress bacterial growth and the resulting inflammation earlier in that scenario. His usual regimen involves roughly one month of inhaled antibiotics followed by a month off, repeated long-term, though he adjusts duration for individual patients, sometimes extending to six weeks or three months before spacing doses further apart.

Dr. Metersky adds that he increasingly favors continuous inhaled antibiotic therapy over the traditional month-on, month-off cycle, since many patients deteriorate during the off month, and pathophysiologically there is little reason to accept added inflammation during that period. When payers approve it, he defaults to continuous therapy unless side effects or toxicity intervene, continuing indefinitely as long as it remains effective.

Dr. ElMaraachli emphasizes why this matters specifically for pseudomonas-colonized patients: oral antibiotic options effective against the organism are limited, and once resistance develops or intolerance occurs, patients are left dependent on intravenous antibiotics for exacerbations. This dynamic, he says, underscores why inhaled antibiotics play such a crucial suppressive role in this population.

Up next, in "DPP1 Inhibition in Bronchiectasis: Mechanism and Pivotal Trial Data," Dr. ElMaraachli and Dr. Khabbaza explain the science and trial data behind DPP1 inhibition.